Avaxia Biologics is developing Guardian Antibodies™ for oral treatment of GI disorders.

Guardian Antibodies™ are polyclonal antibodies that target the oral cavity and the lumen of the gut, extending the reach of antibody therapeutics to new molecular targets and clinical indications.

Avaxia's lead program is a product for mucositis, the painful inflammation and ulceration caused by cancer chemotherapy and radiation therapy.